Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924241 | 0.79 | ALDH1A1 (0.42) | CYP2C19TSHRLMNATDP1MEN1 | |
| SCHEMBL2191989 | 0.73 | ADAM17 (0.62) | CYP2C19TSHRLMNAADAM17 | |
| SCHEMBL3400918 | 0.73 | ADAM17 (0.62) | CYP2C19TSHRLMNAADAM17 | |
| SCHEMBL4123231 | 0.73 | ADAM17 (0.62) | CYP2C19TSHRLMNAADAM17 | |
| Mephenytoin SCHEMBL21766 | 0.67 | CYP2C19 (1.00) | CYP2C19TSHRLMNATDP1MEN1 | |
| SCHEMBL11255982 | 0.67 | CYP2C19 (0.53) | CYP2C19TSHRLMNATDP1MEN1 | |
| Mephenytoin SCHEMBL21768 | 0.67 | CYP2C19 (1.00) | CYP2C19TSHRLMNATDP1MEN1 | |
| Mephenytoin SCHEMBL4778454 | 0.67 | CYP2C19 (0.91) | CYP2C19TSHRLMNATDP1MEN1 | |
| SCHEMBL7243423 | 0.65 | CYP2C19 (0.50) | CYP2C19TSHRLMNATDP1MEN1 | |
| SCHEMBL8109132 | 0.64 | CYP2C19 (0.45) | CYP2C19TSHRLMNATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | BROWN TRUMAN R | 2006-04-27 | — | — | US | disclosed |
| US-5534540-A | CROSSLINKING AND DISCOLORATION INHIBITION; PRESERVING FOODS; AGING RESISTANCE | ALTEON INC. (US) | 1996-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | ALDOA, FBP1, GYS2 | CYP2C19 2548/4885TSHR 4770/4885LMNA 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.